TrialClinical and translational science2024

Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease.

Aaron Koenig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.